Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer’s disease, offering hope for slowing its progression. These laboratory-produced molecules are designed to ...

A new Swedish study has, for the first time, shown a link between rheumatoid arthritis (RA) and cognitive decline in dementia ...

Intermittent fasting may be the key to slowing or even reversing the signs of Alzheimer's disease, a new study suggests.

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Social determinants of health, such as Area Deprivation Index scores, may be considered mild cognitive impairment risk factors among older adults.

For patients with psychiatric conditions from addiction to mood disorders such as depression, disrupted sleep can often ...

Children over the age of two and adults with Lennox-Gastaut syndrome (LGS) in Scotland can now be prescribed the ...

Though antioxidants are good for your health, taking them in supplement form is often unnecessary and can pose risks. Here's ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease. The study demonstrates that the drug improves memory deficits and reverses brain cell damage, ...

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of ...